Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Hypoxia-activated prodrugs (HAP) offer targeted cancer therapy by selectively eliminating hypoxic tumor cells.
• CP-506 is a DNA alkylating HAP with promising pharmacological properties for cancer treatment.

Purpose of the Study:

• To evaluate the hypoxia-selectivity and antitumor activity of the DNA alkylating hypoxia-activated prodrug, CP-506.
• To characterize the biochemical properties of CP-506 relevant to oxygen-sensitive bioactivation.

Main Methods:

• Fast-reaction radiolytic methods were used to characterize CP-506's reduction stoichiometry, electron affinity, and back-oxidation rate.
• In vitro cytotoxicity assays in 2D and 3D cell cultures under varying oxygen concentrations were performed.
• Gain-of-function studies assessed metabolic resistance to aerobic pathways and retention of hypoxic bioactivation.
• In vivo studies in hypoxic xenografts evaluated antitumor effects and correlation with tumor oxygenation.

Main Results:

• CP-506's parameters confirmed its suitability for oxygen-sensitive bioactivation, with maximal inhibition of reduction and metabolism occurring above 1 μmol/L oxygen.
• Selective cytotoxicity was observed in hypoxic cells (normoxic/anoxic IC50 ratios up to 203).
• CP-506 resisted aerobic metabolism by AKR1C3 but retained hypoxic bioactivation by diflavin oxidoreductases.
• In vivo, CP-506 reduced tumor hypoxia, inhibited xenograft growth, and its efficacy correlated with baseline hypoxia and in vitro sensitivity.

Conclusions:

• CP-506 demonstrates significant hypoxia-selectivity and potent antitumor activity against a range of hypoxic tumors.
• Tumor hypoxia and cellular sensitivity to CP-506 are key determinants of its therapeutic efficacy.
• CP-506 represents a promising targeted therapy for hypoxic solid tumors.